BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 22
• 23
• 24
• 25
• 26
• 27
• 30
• 31

• Press Releases

  Alzheon to Present Clinical, Imaging, and Fluid Biomarker Results from Trials with Oral Valiltramiprosate/ALZ-801 at 2026 AD/PD Conference in Copenhagen, Denmark

  March 10, 2026

   · 

  11 min read
• Press Releases

  Centauri Therapeutics Granted FDA QIDP Status for CTX-187 Treatment of Gram-Negative Bacterial Infections

  March 10, 2026

   · 

  3 min read
• 

  IgA nephropathy

  Vertex’s Nephropathy Asset Delivers ‘Strong’ Late-Stage Data, Clears Path to FDA
  

  Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetacicept in IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the end of March.

  March 10, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Duchenne muscular dystrophy

  Dyne Plans Post-Prasad FDA Run as Duchenne Exon Skipper Sustains Benefit in Long Term Data

  Dyne Therapeutics is plotting an approval application for z-rostudirsen in the back half of 2026—a push that will only be bolstered by the departure of controversial CBER chief Vinay Prasad, according to analysts at Stifel.

  March 10, 2026

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Manufacturing

  Cell and Gene Therapy Manufacturing Market To Skyrocket to $146B by 2032

  Analysts expect the market for manufacturing cell and gene therapies, worth less than $20 billion in 2024, to expand rapidly as approvals drive higher volumes of production.

  March 10, 2026

   · 

  3 min read

   · 

  Nick Paul Taylor
• Press Releases

  BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

  March 10, 2026

   · 

  8 min read
• Press Releases

  BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

  March 10, 2026

   · 

  35 min read
• Press Releases

  Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

  March 10, 2026

   · 

  9 min read
• Press Releases

  Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark Report

  March 10, 2026

   · 

  12 min read
• Press Releases

  NMD Pharma late breaking oral presentation at the MDA Conference with top-line safety and efficacy data from SYNAPSE-CMT, an exploratory Phase 2a clinical study of ignaseclant in Charcot-Marie-Tooth disease Types 1 & 2

  March 10, 2026

   · 

  8 min read